Leading BioSolutions Platform

Proforma Financial Results: Q2 FY2020 UPL Crore FY 20 FY19 Change Particulars Q-2 Q-2 * % % % (Note 1) Total Revenue from operation 7,817 100% 7,066 100% 11% Variable Cost 4,546 3,916 16% Gross Margin 3,271 42% 3,150 45% 4% Fixed Overheads EBITDA 1,730 1,541 1,766 -2% 20% 1,384 20% 11% Note: 1) Previous years numbers (including Arysta) have been regrouped for comparison purpose. 46

View entire presentation